Imaging test for invasive mold infections
Part of Infections, Lungs & breathing clinical trials.
This study tests a new imaging agent that may help doctors see mold infections in the body. It involves healthy volunteers and people with mold infections, and aims to improve how these infections are detected and monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must be able to read, understand, and sign the consent form.
- You must be willing to follow all study procedures and be available for the duration of the study.
- If you are a healthy volunteer, you must be generally healthy as determined by the doctors.
- If you have a mold infection, it must be diagnosed as proven or probable by specific criteria.
- If you are of childbearing potential, you must use an acceptable form of birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how immune system problems relate to fungal infections, using medical records and lab tests on blood and tissue. It may help researchers understand the cause of these infections—especially for people with inherited immune conditions—and improve future care.
This study uses a special PET/CT scan with a new tracer to see how TB infection looks in the lungs. It may help doctors better understand and treat TB.
This study uses noninvasive breathing/relates imaging (MRI or CT) to help diagnose mold infections in the lungs in children and young adults. It may help doctors find these infections sooner, especially in people with weakened immune systems.
This study tracks how your immune system responds to serious mold infections, like aspergillosis or mucormycosis. It may help doctors understand why some infections are hard to treat and could lead to better care.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
This study will use special scans to see how an inhaled antifungal medicine (amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis. The results may help doctors choose better treatments in the future.
Hear when a new Aspergillos trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.